Prothena Corporation

Prothena Corporation ROA

The Return on Assets (ROA) of Prothena Corporation (PRTA) as of Oct 2, 2026 is -74.69 %. In the previous year, Return on Assets (ROA) was -22.36 % — a change of 234.10% (lower).

ROA

-74.69 %

YoY

234.10%

Last updated:

In 2026, Prothena Corporation's return on assets (ROA) was -74.69 %, a 234.10% increase from the -22.36 % ROA in the previous year.

The Prothena Corporation ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-31.20 USD
Jan 1, 2019
-18.53 USD
Jan 1, 2020
-33.38 USD
Jan 1, 2021
10.99 USD
Jan 1, 2022
-15.43 USD
Jan 1, 2023
-21.11 USD
Jan 1, 2024
-22.36 USD
Jan 1, 2025
-74.69 USD
The Prothena Corporation ROA history
YEARROAYoY
-74.69 %+234.10%
-22.36 %+5.89%
-21.11 %+36.85%
-15.43 %-240.37%
10.99 %-132.93%
-33.38 %+80.17%
-18.53 %-40.63%
-31.20 %+1.07%
-30.87 %-11.30%
-34.81 %+66.34%
-20.93 %+790.03%
-2.35 %—
Access this data via the Eulerpool API

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

ROA Details

Understanding Prothena Corporation's Return on Assets (ROA)

Prothena Corporation's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Prothena Corporation's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Prothena Corporation's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Prothena Corporation’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Prothena Corporation stock

Return on Assets (ROA) of Prothena Corporation is -74.69 % in 2026.

Return on Assets (ROA) of Prothena Corporation changed from -22.36 % to -74.69 %, representing a 234.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Prothena Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Prothena Corporation

All Key Metrics — Prothena Corporation